Clients using Semaglutide GLP-1 for weight management have achieved substantial, sustained reductions in body weight over time
GE2 treatment reduced inflammation in the dorsal and ventral hippocampus, however only in SD subjects, regardless of sex, as well as in the amygdala in males regardless of diet
However, future studies are needed to explore the pathophysiology of GLP-1RAs in individuals with type 2 diabetes and NAFLD and to determine the optimal use of GLP-1RAs to prevent adverse CVEs
Some report that a smaller dose allows them to: Maintain a healthy appetite while reducing food noise Support long-term metabolic health Avoid some of the gastrointestinal side effects that can occur with higher doses Take a more gradual, sustainable approach Again, there is limited research specifically evaluating long-term "microdosing" strategies, so decisions should always be individualized and made with a qualified healthcare professional
Tolerance to the gastric slowing effect often develops over time with long-acting agents, which may reduce GI side effects after initial weeks
Their effects are wide-ranging, and adolescence is a critical window when those effects can be most significant